$1.$ Booth Pharma Inc. $($BPI$)$ manufactures generic drugs. BPI had sales of $\backslash (\backslash$$ $20\backslash )$ billion in the most recent fiscal year $($FY$2024).$ Analysts expect BPI's sales to grow at the following rate The long$-$run growth rate of the generic drug industry is $\backslash (2\backslash \%\backslash ).$ Based on BPI's past profitability and investment needs, analysts expect EBIT to be $\backslash (10\backslash \%\backslash )$ of sales, increases in net working capital requirements to be $\backslash (10\backslash \%\backslash )$ of any increase in sales, and capital expenditures to equal depreciation expenses. The corporate tax rate is $\backslash (21\backslash \%\backslash ).$ The firm has adopted the following capital structure $($as on end of FY$2024)-$ Debt to Assets ratio $=20\backslash \%-$ Debt $\backslash (=\backslash$$ $6\backslash )$ billion $($perpetual$)-$ Cash $\backslash (=\backslash$$ $1\backslash )$ billion $-$ Interest rate on debt $\backslash (=9\backslash \%\backslash )($constant$)-$ Unlevered Cost of Equity $\backslash (=15\backslash \%\backslash )-$ Number of shares $\backslash (=100\backslash )$ million What would have been your estimate of the value $($per share$)$ of BPI's stock in early $2025?$ Use $($a$)$ APV method $($b$)$ WACC method $($c$)$ FTE method $.(10$ points for each method$)$